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Abstract
Objectives
To estimate the nationwide population-based incidence, prevalence, and geographical distri-
bution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on
the 2015 International Panel for NMO Diagnosis (IPND) criteria.
Methods
We conducted a multicentre, historically prospective study. Data were sourced from the Danish
National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology,
and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006
Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.
Results
We conﬁrmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria)
between 2007 and 2014. Deﬁned by the 2006 criteria, the incidence of NMO was 0.029 per
100,000 person-years (95% conﬁdence interval [CI] 0.014–0.051), and the prevalence (aged
16 years and older) was 0.566 per 100,000 (95% CI 0.370–0.830). Based on the 2015 IPND
criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046–0.102),
and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808–1.440),
without regional diﬀerences.
Conclusions
Our estimates of incidence and prevalence are similar to other Caucasian population–based
studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.
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Neuromyelitis optica (NMO)/NMO spectrum disorder
(NMOSD) is a chronic, recurrent, antibody (Ab)-mediated,
inﬂammatory disease aﬀecting distinct areas of the CNS.1
Since the recognition of aquaporin-4 (AQP4) Ab,2 diﬀerent
NMO/NMOSD classiﬁcations have been proposed. The
term deﬁnite NMO was applied to describe longitudinally
extensive transverse myelitis (TM) together with optic neu-
ritis (ON) regardless of the presence of AQP4-Ab.3,4 The ﬁrst
deﬁnition of NMOSD was used to deﬁne the spatially limited
syndromes of AQP4-Ab–seropositive ON or longitudinally
extensive TM.5 The 2015 International Panel for NMO Di-
agnosis (IPND) criteria made it possible to diagnose AQP4-
Ab–seropositive NMOSD with at least 1 of the 6 core clinical
symptoms. In AQP4-Ab–seronegative cases, at least 2 of the 6
core clinical features supported by MRI lesion are required,
and one of the clinical features has to be 1 of the 3 most
common clinical features (ON, TM, area postrema syn-
drome).6 Anti-myelin oligodendrocyte glycoprotein (MOG)
Abs that target the oligodendrocytes may be detected in
AQP4-Ab–seronegative NMOSD.7
Previous epidemiologic studies are diverse in the size of the
target population, the method of case ascertainment, and the
AQP4-Ab measurement (table 1). There are only a few
population-based epidemiologic NMOSD studies applying
the 2015 IPND criteria.8–13
The aim of this population-based study was to estimate the
incidence and prevalence of NMOSD in the entire Danish
adult population according to the 2006 Wingerchuk and the
2015 IPND criteria by utilizing comprehensive datasets, and
to assess diﬀerences between the 5 Danish regions.
Methods
Study design
This Danish nationwide study is based on collaboration and
data acquisition from all 14 neurologic departments with re-
sponsibility for the management of patients with immune-
mediated CNS disorders. The target population comprised all
patients diagnosed with NMO, ON, TM, multiple sclerosis
(MS) with ON or TM as presenting symptom, or those tested
for AQP4-Ab from January 1, 2007, to December 31, 2014.
Data collection from these patients continued until July 1,
2016. We estimated the prevalence of patients aged 16 years
and older, because the registration of patients younger than
age 16 at prevalence day would probably be incomplete, as we
had no arrangements with the pediatric departments. How-
ever, patients with onset before age 16 were included in the
incidence analysis because after diagnosis they are regularly
followed up at the departments of neurology.
The entire Danish population has access to tax-funded, free-
of-charge health care. Four specialized university hospitals
(Aalborg, Aarhus, Odense, Rigshospitalet) are in charge of the
clinical care of patients with NMOSD. Other departments are
requested to refer all newly diagnosed patients with NMOSD
to these centers.
Sources
Multiple sources were combined for the best coverage (ﬁgures
1 and 2):
1. The Danish National Patient Registry, established in
1977, has collected data on all admissions and outpatient
visits since 1995. It includes information about the
hospital department, admission and discharge dates, and
discharge diagnoses, according to the ICD-10.14 We
included all patients registered with NMO/Devic disease
(DG36.0), ON (DH46.9), and acute TM (DG37.3)
between January 1, 2007, and December 31, 2014.
2. The Danish Multiple Sclerosis Registry has been
collecting data on MS since 1948.15,16 All Danish citizens
diagnosed with MS or suspected MS by a neurologist are
notiﬁed in the Danish Multiple Sclerosis Registry and
reclassiﬁed by an MS expert at the time of data entry,
based on the medical records. Patients with MS who had
ON or TM as the presenting symptom were reevaluated
for possible NMO/NMOSD.
3. Laboratories providing AQP4-Ab detection tests in
Denmark supplied the list of patients tested for this Ab.
These laboratories are the Statens Serum Institute (SSI), the
Department of Clinical Immunology at Odense University
Hospital (OUH), and theNeuroimmunology Laboratory at
the Danish Multiple Sclerosis Center, Rigshospitalet,
University of Copenhagen (RH). In total, 4,067 samples
from 3,397 patients were tested within the study period.
4. All departments of neurology were asked to report any
NMOSD and possible NMOSD cases.
To ensure the highest possible quality of data, we excluded
patients who had never been seen at any public neurology
departments or if crucial clinical information was missing.
Glossary
Ab = antibody; AQP4 = aquaporin-4; CBA = cell-based assay; CI = conﬁdence interval; DMT = disease-modifying therapy;
ICD-10 = International Classiﬁcation of Diseases, Tenth Revision; IPND = International Panel for Neuromyelitis Optica
Diagnosis; MOG = myelin oligodendrocyte glycoprotein;MS = multiple sclerosis; NMO = neuromyelitis optica; NMOSD =
neuromyelitis optica spectrum disorder; ON = optic neuritis; OUH = Odense University Hospital; RH = Neuroimmunology
Laboratory at the Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen; SSI = Statens Serum Institute;
TM = transverse myelitis.
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Table 1 Heterogeneity of the previous epidemiologic studies conducted in Caucasian and non-Caucasian populations
Country Population (million) Source Criteria AQP4 test
Incidence/
100,000
Period of
incidence rate
Prevalence/
100,000
Percentage of
seronegative cases
Caucasian
Southern Denmark
(Denmark)24
0.952 (age ≥15 y) Multiple: registry,
department
2006 seropositive ON/
LETM
CBA,
immunoprecipitation
assay
0.4 Not specified 4.4 38
South East Wales (UK)25 0.713 (FP) Multiple: registry,
laboratory, department
2006 seropositive ON/
LETM
Not reported NA NA 1.96 28
Northwest England
(UK)26
1.14 (age >16 y) Multiple: registry,
laboratory, department
2006 seropositive ON/
LETM
CBA 0.08 2003–2010 0.72 12
Austria23 8.4 (FP) Multiple: department,
laboratory
Only AQP4-seropositive
NMO/NMOSD
CBA 0.054 2008–2011 0.7 Not included
Isfahan Province
(Iran)32
Not specified Single: registry 2006 Not specified NA NA 1.9 33.7
Southwest Iran (Iran)31 4.5 (FP) Multiple: department and
MS Society
2006 seropositive
NMOSDa
Not specified NA NA 1.1 Not specified
Olmsted County (MN)27 0.146 (FP) Multiple: registry,
department
2006 seropositive
NMOSDa
CBA 0.07 2003–2011 3.9 17
Tehran (Iran)12 1.2 (FP) Single: department 2015 ELISA NA NA 0.86 53.2
Australia and New
Zealand8
27.67 (FP) Multiple: department,
laboratory
2015 CBA (46%), IF-tissue
assay (100%)
0.037 2009–2012 0.7 10
Catalonia (Spain)9 7.52 (FP) Multiple: registry,
laboratory, department
2015 CBA (96%),
immunohistochemistry
(3%), ELISA (1%)
0.063 2006–2016 0.89 27
Central Denmark
Region (Denmark)11
1.27 (FP) Single: department 2015 ELISA, anti-AQP4 IIFT 0.12 2012–2013 NA Not specified
Non-Caucasian
Cuba28 11.18 (FP) Multiple: registry,
department
2006 Not specified 0.053 2003–2004 0.52 Not specified
Tokachi Province
(Japan)33
0.352 (FP) Single: department 2006 CBA NA NA 0.9 0
Mangalore (India)30 0.419 (FP) Single: department 2006 seropositive ON/
LETM
Not specified NA NA 2.6 Not specified
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The minimum data required for seronegative NMOSD cases
were clinical features and brain and spinal cord MRI once,
respectively. For seropositive cases, clinical data and AQP4-
Ab seropositivity were required, but practically all patients had
brain and spinal MRI at least once. We also excluded foreign
citizens who had left Denmark.
Case selection
Medical records and MRIs of all patients from the above-
mentioned sources were reevaluated. The following information
was included in the research dataset: age; age at onset; city of
residence; family history; ethnicity; autoimmune comorbidities,
history of all relapses; clinical course; response to immuno-
suppressive and immunomodulatory therapy; all available brain
and spinal cord MRIs performed at the time of diagnosis and
during follow-up; all AQP4-Ab results; method of AQP4-Ab
test; visual-evoked potentials; spinal ﬂuid examination (cell
count, protein concentration, immunoglobulin G index, oligo-
clonal bands); presence of other autoantibodies; and the results
of clinical examinations to exclude alternative diagnoses.
We selected patients with possible NMOSD who met one of
the following criteria for further case validation: (1) at least
one positive AQP4-Ab test result; (2) according to the
medical records, treatment for NMOSD or diagnosis of
NMOSD at any time; and (3) suspicion of NMOSD based on
the 2015 IPND criteria.6
Case validation
The ﬁnal validation of the selected cases was done by an
expert panel (the coauthors F.S., Z.I., J.F., T.P., E.S.). This
panel of 5 neurology professors with treating responsibility for
patients with NMOSD in Denmark anonymously and in-
dependently reviewed the data of all patients who were en-
rolled during the selection. The expert panel assessed the
complete dataset including the clinical, neuroimaging, and
laboratory data during the reevaluation. All ﬁnal diagnoses
were reached by a consensus decision.
AQP4- and MOG-Ab tests
All patients who fulﬁlled the selection criteria were previously
tested at least once for AQP4-Ab. Samples collected at di-
agnosis or when the tests became available were tested for
AQP4-Ab in at least one of the following laboratories: Mayo
Clinic (Rochester, MN); John Radcliﬀe Hospital (Oxford,
UK), Seeling Labs (Karlsruhe, Germany), RH (Copenhagen,
DK), SSI (Copenhagen, DK), and OUH (Odense, DK)
(Mayo Clinic: tissue-based immunoﬂuorescence assay; Ox-
ford John Radcliﬀe Hospital: CBA [cell-based assay]; Seeling
Labs: in vitro translation/immunoprecipitation assay; RH:
ELISA kit [EA111/96; DLD Diagnostika GmbH, Hamburg,
Germany]; SSI: CBA; OUH:CBA [EUROIMMUN, Luebeck,
Germany]). The following is the proportion of the assays used
for the AQP4 test: 79.5% were tested with CBA, 13.7% of the
patients were tested only with immunoprecipitation assay,
6.8% were tested only with ELISA, and 1 typical NMOSD case
was analyzed with only tissue-based assay.Ta
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At the SSI laboratory, the CBA for AQP4-Ab was validated by
comparison with the CBA used at John Radcliﬀe Hospital, Ox-
ford. The OUH laboratory uses the commercially available CBA
(EUROIMMUN). After 5 years of experience interpreting the
semiquantitative assay, OUH laboratory participated in a multi-
center comparison study of AQP4 assays, with good results.17
In general, we took CBA performed in Oxford as a gold stan-
dard when it was done. In other cases, the result of the
EUROIMMUN CBA (which is widely used) was considered,
but when the clinical, laboratory, radiologic features, and the
repeated inconsistent AQP4-Ab test result raised concern about
the diagnosis of NMOSD, the case was reviewed by the expert
panel. There were 429 patients tested with ELISA, and 46% of
the same blood samples were retested with CBA in Oxford. In
all of these cases, CBA was negative if the ELISA was negative.
Samples from patients, in which there was a high clinical sus-
picion of NMOSD but ELISA screening was negative, were
tested with CBA in Oxford. All samples positive with ELISA
were also analyzedwithCBA at JohnRadcliﬀeHospital, Oxford.
TheMOGAb tests were undertaken by CBA at John Radcliﬀe
Hospital, Oxford.18
Statistical analysis
Among the eventually included cases, we counted individuals
notiﬁed from the laboratories as “captures” and individuals
notiﬁed by the departments (either directly or through the
National Patient Registry or MS Registry) as “recaptured.”
We used the Chapman19 estimator, which is regarded to be
less biased with small sample sizes (ﬁgure 2).
The incidence and prevalence were estimated according to
2006 and 2015 criteria.3,6 We calculated incidence up to and
including 2013 and prevalence for January 1, 2014, since as-
certainment after this time may be incomplete because of the
potential delay in diagnosis. The median time from the pre-
senting symptom to the ﬁrst relapse was up to 12 months in
the Caucasian population, even in seropositive AQP4 cases.20
Incidence rates with the 95% conﬁdence interval (CI) were
calculated by using Poisson distribution from number of
Figure 1 Flowchart summarizing the ascertainment process of the patients with NMOSD
Flowchart demonstrates the strategy of patient
selection and validation in the Danish population of
age 16 years andolder. AQP4 = aquaporin-4; IPND=
International Panel for Neuromyelitis Optica Di-
agnosis; MS = multiple sclerosis; NMOSD = neuro-
myelitis optica spectrum disorder.
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new-onset NMO/NMOSD cases between January 1, 2007,
and December 31, 2013, and the full population number of
person-years at risk 2007 through 2013 as denominator.
Prevalence was determined by the number of patients with
NMO/NMOSD alive at age 16 years and older as numerator
per 100,000 persons in the adult population (age 16 or older)
as denominator. Quantitative variables are given as median
and range. Data management and analyses were conducted
using SPSS software (version 22; IBM Corp., Armonk, NY)
and Excel Visual Basic (Microsoft, Redmond, WA).
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Danish Data Protection
Agency (J no. 1-16-02-658-15) and the local ethical com-
mittee (Ethical Committee for The Region of Central Jutland;
J no. 1-10-72-346-15).
Data availability
Data were carefully documented in the methods and results
sections. Data are also available from Dryad (appendix 1, doi.
org/10.5061/dryad.369417f). Further anonymized data can
be shared by request from any qualiﬁed investigator.
Results
Patient selection and validation
The Danish population aged 16 years and older was 4,590,391
(female: 50.74%) on January 1, 2014, and included 95.2% of
individuals born in Europe, 3.5% in Asia, 0.8% in Africa, and
0.5% in other countries.21
The combined sources had notiﬁed us of 4,138 persons to be
screened for this NMO/NMOSD study. We identiﬁed 55
adult patients with at least one positive AQP4-Ab test per-
formed with the suggested CBA.6 After excluding some cases
at diﬀerent steps of the screening and analysis process (see the
study ﬂowchart in ﬁgure 1), we had 56 patients with a con-
ﬁrmed diagnosis of NMOSD, according to the 2015 criteria,
with onset within the study period between January 1, 2007,
and December 31, 2014. Of those 56 patients, 30 also met the
2006 NMO criteria.
In the last step of validation, 16 patients were excluded (data
available from Dryad, appendix 1, doi.org/10.5061/dryad.
369417f). These patients had AQP4-Ab positivity (at low
level) by CBA; the subsequent samples were negative in 14
of the 16 cases. The ﬁnal diagnoses of these patients were
MS (n = 13), monophasic idiopathic TM (n = 1), mono-
phasic mild ON (n = 1), and probable recurrent idiopathic
ON (n = 1). Median number of red ﬂags for NMOSD by
Wingerchuk et al.6 was 6 in the 13 patients with a ﬁnal di-
agnosis of MS (table 2). Seven of the 13 patients had been
treated with disease-modifying therapy (DMT) and were
stable. One patient stopped DMT and remained clinically
stable. Another 3 patients had never been treated, and 2
patients had a progressive disease course despite DMT (data
available from Dryad, appendix 1, doi.org/10.5061/dryad.
369417f).
The median age at disease onset was 35.5 years (range 5–76).
Disease onset before the age of 16 years was recorded in 7
patients (12.5%), and at older than 50 years in 19 patients (34%).
The median years of follow-up was 8 years (range 1–46).
The female/male ratio was 4.6:1. In the seropositive group,
this ratio was 12:1 but only 1.3:1 in the seronegative NMOSD
group (Fisher exact test, p = 0.0055).
Regarding ethnical background, 50 patients (89.3%) were
Caucasians, 4 (7.1%) Asians, 1 (1.8%) was Arabian, and 1
(1.8%) African.
Of the 17 AQP4-Ab–seronegative cases included, 9 (53%) had
MOG Abs, 2 (12%) were double-seronegative, and 6 (35%)
were not tested for MOG Abs.
Capture-recapture analysis
Two-sample capture-recapture analysis estimated that the
“true” number of cases should be 56.2 so that the com-
pleteness is almost unity. The upper 95% conﬁdence limit
was 57.1.
Incidence and prevalence of NMObased on the
2006 criteria
There were 11 incident cases over the period of 2007–2013
emerging from the background population observed for
38,449,668 person-years. Hence, the NMO incidence was
0.0286 per 100,000 person-years (95% CI 0.0143–0.0512).
Figure 2 Sources of notification of the 56 included patients
with neuromyelitis optica spectrum disorder
Venn diagram shows that we were able to identify all cases from the
departments and laboratories. The NPR (National Patient Registry) and
DMSR (Danish Multiple Sclerosis Registry) did not contribute with unique
cases. Capture-recapture analysis requires that notification by a second
source is independent of notification by the first source. Because bothDMSR
and NPR are strongly mutually dependent and also dependent with the
departments, we treated them as a single source.
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The prevalence analysis included 26 NMO alive cases and
the Danish population at age 16 and older as 4,590,391 by
January 1, 2014, giving a national prevalence rate of 0.566
per 100,000 persons (95% CI 0.370–0.830). Sex- and se-
rologic status-speciﬁc incidence and prevalence rates are
also shown in table 3.
Incidence and prevalence of NMOSD based on
the 2015 IPND criteria
We identiﬁed 27 patients with onset in the period 2007–2013,
resulting in an incidence of NMOSD of 0.0702 per 100,000
person-years (95% CI 0.0463–0.1022). Five of 56 patients
died before the prevalence date and one had disease onset
after January 1, 2014, leaving 50 patients at age 16 years and
older. Hence, the prevalence rate was accordingly 1.09 per
100,000 persons (95% CI 0.808–1.440). Further results of
incidence and prevalence rates stratiﬁed by sex and serologic
status are shown in table 3.
Prevalence in the Caucasian population was 1.007 (95% CI
0.732–1.35) and it was 2.47 (95%CI 0.674–6.33) in the Asian
population.
By applying the 2015 criteria, the prevalence increased 1.9-
fold and incidence 2.4-fold compared to 2006 criteria. In 17
seropositive patients with one clinical core criterion and in 9
seronegative patients, NMOSD was diagnosed based only on
the new criteria.6
Prevalence of NMOSD based on 2015 IPND
criteria in the Danish regions
No statistically signiﬁcant diﬀerences were found in the
prevalence rates (per 100,000 persons) among the 5 Danish
regions (p = 0.88) (table 4).
Discussion
This Danish nationwide population-based study combining
data from population-based disease registries, laboratories,
and hospitals generates an incidence estimate of 0.070 per
100,000 person-years and a prevalence of 1.09 per 100,000
persons according to 2015 IPND criteria. In general, our data
are in line with previous epidemiologic studies in Caucasian
populations. We observed an equal distribution of patients
with NMOSD among the 5 Danish regions.
When the prevalence and incidence of an uncommon chronic
disease are estimated, certain conditions are required to gain
reliable and generalizable results. The sample size and the
duration of observation can be critical for the assessment of
the epidemiologic features of these conditions.22
In Denmark, AQP4-Ab measurement became available in
December 2007, and since then, a large number of patients
were tested. Therefore, we only included patients with clinical
onset from 2007 to the end of 2014 and with follow-up by July
1, 2016. This broad timeframe is helpful to ensure the accu-
racy of the given NMOSD diagnosis, to rule out alternative
diagnoses, and to compensate for delay between onset and
diagnosis.
The absolute number of Danish patients (3,397 patients)
tested for AQP4-Ab is more than twice as many as in the
Austrian study (1,557 patients) and 3 times more compared
to the Catalonia study (1,187 patients).9,23 This shows that
AQP4 analysis was performed in a higher proportion of the
population in Denmark compared to other countries.
The main characteristics of the previous studies are summa-
rized in table 1. Most of the available epidemiologic outcomes
were estimated according to the 2006Wingerchuk criteria.24–33
Many of these reports also included the limited form of AQP4-
seropositive ON and TM or seropositive NMOSD.24–27,29–31
Two studies conducted in Caucasian populations based on the
2015 criteria applied study design comparable to our study.
Table 2 Red flags for NMOSD in the low AQP4
antibody–positive patients with final diagnosis of
multiple sclerosis
Cases
(n = 13)
Follow-up, y, median (range) 15 (7–34)
Seroconversion from positive to negative 13 (100)
Red flagsa
1. Clinical or laboratory features
Progressive clinical course 4 (30.8)
Duration of relapse <4 h or worsening >4 wk 6 (46.2)
Partial transverse myelitis 9 (76.9)
CSF oligoclonal bands (n = 12) 11 (91.7)
Comorbidities: sarcoidosis, cancer,
chronic infection
0
2. MRI features (brain and spinal cord)
Dawson fingers 11 (84.6)
Adjacent to lateral ventricles in the
inferior temporal lobe
4 (30.8)
Juxtacortical lesion 6 (46.2)
Cortical lesion 0
Persistent gadolinium-enhancing brain lesion 0
Spinal cord lesion shorter than 3 segments (n = 12) 8 (66.6)
Peripheral spinal cord lesion (n = 9) 8 (88.9)
Diffuse, indistinct T2 spinal cord lesion (n = 12) 4 (33.3)
3. No. of red flags, median (range) 6 (3–8)
Abbreviations: AQP4 = aquaporin-4; NMOSD: neuromyelitis optica spec-
trum disorder.
Data are n (%) unless otherwise indicated.
a According to the 2015 International Panel for Neuromyelitis Optica Di-
agnosis criteria.
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These research groups also utilized multiple sources and
performed CBA for AQP4 measurement in the majority of the
cases similarly to this cohort. In the study from Australia/New
Zealand with a population of 27.7 million, the prevalence of
NMOSD was 0.7, signiﬁcantly lower than the 1.09 in our
study.8 In the study conducted in the Catalonian population
comprising a population of 7.5 million, the prevalence was 0.89,
which corresponds well to our results.9 The diﬀerence may
have arisen from the fact that the 2 other studies included the
whole population age range, while we restricted our analyses
of prevalence to cases and population with age of 16 years
and older. Indeed, NMOSD is rarer in children than in
adults.9 We also identiﬁed more AQP4-seronegative patients
in Denmark (Australia 10% and Catalonia 27% vs Denmark
Table 3 Incidence and prevalence of the Danish NMO/NMOSD population based on the 2015 IPND criteria and the 2006
Wingerchuk criteria also stratified by sex and serologic status
Background
population
age ≥16 y
(January 1,
2014)
2015 IPND criteria 2006 Wingerchuk criteria
Prevalence per 100,000 Prevalence per 100,000
Prevalent
cases
(January 1,
2014) Prevalence 95% CI
Prevalent
cases
(January 1,
2014) Prevalence 95% CI
All 4,590,391 50 1.090 0.808–1.440 26 0.566 0.370–0.830
Female 2,329,255 41 1.760 1.260–2.390 23 0.987 0.670–1.480
Male 2,261,136 9 0.398 0.180–0.760 3 0.133 0.027–0.388
AQP4 seropositive 4,590,391 35 0.762 0.531–1.060 20 0.436 0.266–0.673
AQP4 seronegative 4,590,391 15 0.327 0.180–0.540 6 0.131 0.048–0.284
NMOSD without MOG-
seropositive cases
4,590,391 42 0.915 0.659–1.240 23 0.501 0.318–0.752
Background
population
(person-
years)
Incidence per 100,000 person-years Incidence per 100,000 person-years
Incident
cases
(2007–2013)
Incidence
rate 95% CI
Incident
cases
(2007–2013)
Incidence
rate 95% CI
All 38,449,668 27 0.0702 0.0463–0.1022 11 0.0286 0.0143–0.0512
Female 19,328,899 20 0.1035 0.0632–0.1598 9 0.0466 0.0213–0.0884
Male 19,120,769 7 0.0366 0.0147–0.0754 2 0.0105 0.0013–0.0378
AQP4 seropositive 38,449,668 18 0.0468 0.0277–0.0741 8 0.0208 0.0090–0.0410
AQP4 seronegative 38,449,668 9 0.0234 0.0107–0.0444 3 0.0078 0.0016–0.0228
NMOSD without MOG-
seropositive cases
38,449,668 22 0.0572 0.0359–0.0866 9 0.0234 0.0107–0.0444
Abbreviations: AQP4 = aquaporin-4; CI = confidence interval; IPND = International Panel for Neuromyelitis Optica Diagnosis; MOG = myelin oligodendrocyte
glycoprotein; NMO = neuromyelitis optica; NMOSD = neuromyelitis optica spectrum disorder.
Table 4 Prevalence of neuromyelitis optica spectrum disorder according to the 2015 International Panel for
Neuromyelitis Optica Diagnosis criteria in the 5 Danish regions
Region Population age ≥16 y (January 1, 2014) Prevalent cases (January 1, 2014) Prevalence per 100,000 95% CI
Capital Region 1,430,139 17 1.19 0.69–1.90
Region Zealand 667,584 5 0.75 0.24–1.75
Region of SouthernDenmark 980,386 11 1.12 0.56–2.01
Central Denmark Region 1,034,105 11 1.06 0.53–1.90
North Denmark Region 478,177 6 1.25 0.46–2.73
Abbreviation: CI = confidence interval.
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30.3%). One-third (35%) of the seronegative NMOSD cases
in our study were retrospectively recognized based on the
2015 criteria.
An Iranian study estimated the prevalence deﬁned only by the
2015 IPND criteria, but patients were identiﬁed from a single
neurology center and AQP4-Abs were measured with ELISA.
Their results disclosed one of the highest proportion of se-
ronegative NMOSD cases (53%) among the studies.12
There are 2 population-based studies that published higher
prevalence compared to our work24,27 and also to recently
published data.8,9 One of these from the Region of Southern
Denmark showed the highest prevalence among the Cau-
casian population and it also reported the highest incidence
among the available studies worldwide.24 In contrast to that
study, our current work applied both criteria (2006 and 2015
criteria), included all patients with NMOSD from the entire
country, and cases with uncertain diagnosis were reassessed
by an expert panel. The present study reviewed all patients
from Denmark who were tested for AQP4-Ab in the period
of 2007–2014, also including the Region of Southern Den-
mark. Our incidence data are also supported by the recent
Danish study from the Region of Central Jutland that found
an incidence rate similar to our nationwide result.11 In the
other recent study that reported similar incidence to our
data but high prevalence in a Caucasian population, the
results may have been inﬂuenced by statistical random
variation because of the small background population
(145,979 persons) and small number of NMOSD cases
(6 patients).27
The superiority of the 2015 IPND criteria over 2006 criteria in
identiﬁcation of both seropositive and seronegative patients
with NMOSD was also indicated by recent studies.9,34 Our
rate of incidence correlates well with most of the previous
studies,9,26,27 except one smaller study.24 It is noteworthy that
the very recent incidence study from the Central Denmark
Region substantiates our ﬁnding of a lower NMOSD in-
cidence in Denmark compared to the previous Danish study
from the Region of Southern Denmark.11,24
Furthermore, incidence and prevalence of seropositive
patients with NMOSD reported here are in line with the
nationwide study from Austria (incidence 0.046 vs 0.054;
prevalence 0.72 vs 0.7).23
The estimated prevalence based on ethnicity demonstrates
2.5-fold–higher prevalence in the subpopulation with Asian
ancestry compared to the Caucasian, similar to the Australian
cohort.8 This result should be interpreted with caution be-
cause of the small number of Asian patients in our cohort.
We found the female/male ratio consistent with other
reports.8,9,25,26 The female predominance in the general
population and in the seropositive population disappears in
the seronegative group.9,35
The strengths of our study include (1) nationwide ascer-
tainment from multiple sources covering a large target pop-
ulation, (2) diagnostic validation by an expert panel based on
all clinical and paraclinical data for each case, (3) the capture-
recapture analysis showed that our estimates of incidence and
prevalence of NMOSD in Denmark is unlikely to be aﬀected
by a notable number of overlooked patients, (4) the majority
of the patients had follow-up for many years, and (5) all
clinical records were evaluated—not only from those patients
who were actively followed up at their neurologic depart-
ments, but also from those who were in remission and did not
require regular neurologic follow-up. This methodology
allowed us to reevaluate the clinical and radiologic aspect of
the disease more robustly than by relying strongly on the
AQP4-Ab measurement. Of note, we removed 16 cases with
false weakly positive AQP4-Ab result measured by CBA
during the introduction period of this laboratory test.
Nevertheless, we may have missed cases presenting only with
the very rare clinical core symptoms since we did not review
patients with every type of demyelinating disorder, such as
area postrema syndrome, encephalitis, or unspeciﬁed de-
myelinating CNS disease. Patients in whom a severe ﬁrst
relapse led to death may have been lost if AQP4measurement
was not conducted at the onset. The utilization of diﬀerent
AQP4 test methods might inﬂuence our results, although we
tried to compensate for this possible weakness by reviewing all
patients’ clinical, laboratory, and radiologic data and a com-
bination of diﬀerent Ab assays. It was not possible to test all
patients fulﬁlling the strict 2015 criteria of seronegative
NMOSD for anti-MOG Abs. Still, our data can be compared
to other studies since they either included patients with MOG
Ab in their cohort9 or they did not measure it,8,12,24,25,27,32
except for the recent Japanese cohort.13
We excluded 102 cases because of insuﬃcient data, but this is
not likely to have a major eﬀect on the validity of our results.
None of the excluded patients were reported by the neuro-
logic departments as possible NMOSD and they were not
registered in the Danish National Patient Registry with NMO.
In total, 55 of them had a negative AQP4 test using CBA, and
in another 12 excluded cases, normalMRI was available. None
of these patients had contact with any Danish neurology
departments for at least 5 years until July 1, 2016, which would
be unexpected in a case of NMOSD, based on the severity of
this condition.
In this study, we found that incidence and prevalence of
NMOSD inDenmark are consistent with those of other studies
in Caucasian populations. We observed no geographical clus-
tering among the regions. Our study conﬁrms that using the
2015 IPND criteria almost doubles the diagnostic sensitivity
compared with the 2006 criteria, especially in the seronegative
group. The independent reassessment of the diagnosis by an
expert panel suggests that cases with mild or uncertain anti-
AQP4 seropositivity should be interpreted with caution and
reevaluated during follow-up.
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